MedTrace Logo

Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease

NCT04121858 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 706

Last updated 2025-03-13

No results posted yet for this study

Summary

This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.

Conditions

Interventions

OTHER

Brain Safe App

The Brain Safe app includes the medication list, a personalized risk calculator, multimedia educational content, and a conversation starter/doctor's report.

OTHER

Attention Control App

The attention control app, called Med Safe, includes only the medication list feature.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Indiana University

    lead OTHER

Principal Investigators

  • Richard J Holden, PhD · Indiana University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-16
Primary Completion
2025-02-27
Completion
2025-02-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04121858 on ClinicalTrials.gov